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Modiﬁed Rodnan skin scoreAbstract Introduction: The role of angiogenesis in the pathogenesis of systemic sclerosis (SSc) is
well known. The imbalance between vascular endothelial growth factor (VEGF) and their anti-
angiogenic soluble receptors (sVEGFR-1 and VEGFR-2) has been proposed as a possible cause
of microangiopathy.
Aim of the work: To determine the levels of VEGF, sVEGFR-1 and sVEGFR-2 and the VEGF/
sVEGFR1 and VEGF/sVEGFR2 ratios in SSc patients and to study their relation with clinical
manifestations and capillaroscopy ﬁndings.
Patients and methods: The study included 44 SSc patients and 44 controls. The sclerosis severity
was assessed by the modiﬁed Rodnan skin score (mRss) and capillaroscopy performed in patients.
Serum VEGF, sVEGFR-1 and sVEGFR-2 were measured in patients and control.
Results: SSc patients had a mean age of 40.7 ± 12.8 years, M:F (1:9) and disease duration was
56.2 ± 60.6 months. 27 patients (61.4%) had diffuse-SSc and 17 (38.6%) limited. The mean VEGF
was signiﬁcantly higher (363.4 ± 133.9 pg/ml) and sVEGFR-2 lower (2039.6 ± 109 pg/ml) inospital,
FR-2 in
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ejr.2016.03.004patients compared to control (93.9 ± 25.2 pg/ml and 2366 ± 116.5 pg/ml; p= 0.05 and p= 0.04,
respectively). Serum levels of sVEGFR-2 in patients with early, active and nonspeciﬁc scleroderma
pattern of capillaroscopy was higher in comparison to patients with late scleroderma pattern
(p= 0.05). There were no signiﬁcant differences in the studied parameters between those patients
with and without digital ulcerations and interstitial pulmonary ﬁbrosis. A signiﬁcant correlation
was found between mRss and VEGF (p= 0.04).
Conclusion: An overproduction of VEGF, a potent angiogenic molecule or down regulated pro-
duction of its natural inhibitors (sVEGFR-2) might be involved in the development of vasculopathy
in SSc patients.
 2016 Egyptian Society of Rheumatic Diseases. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Systemic sclerosis (SSc) is a connective tissue disorder that
affects the skin and internal organs [1]. Microvasculopathy
in the ﬁnger vessels leads to Raynaud’s phenomenon that
can result in digital ischemia [2,3]. Excessive synthesis and
deposition of collagen in the extra-cellular matrix are involved
in the pathophysiology of scleroderma [4]. The vascular injury
in SSc is not an inﬂammatory process, characterized by a vas-
culopathy in the absence of vasculitis [5,6]. An increased risk of
peripheral arterial disease has been reported in SSc [7]. In a
previous study [8], ﬁbroblast growth factor-23 had no obvious
role in the pathogenesis or clinical manifestations of Iranian
SSc patients. Endothelial cell injury is an early and main event
in patients with SSc [9]. High serum level of Von Willebrand
factor [10], endothelin-1 (ET-1) [11], and circulating dead
endothelial cells [12] are involved in endothelial injury and in
the pathogenesis of SSc [6,13].
Higher level of ET-1 has been reported in patients with scle-
roderma renal crisis, pulmonary hypertension and Raynaud’s
phenomenon [14,15]. The vascular endothelial growth factor
(VEGF) is a potent angiogenic peptide and main regulator
of blood vessels by a variety of cell types [16]. Hypoxia and tis-
sue ischemia lead to expression of angiogenic growth factors,
e.g. VEGF [17–19]. Because of its intimate association with
both normal and abnormal angiogenesis, VEGF has become
an attractive target for both proangiogenic and antiangiogenic
therapy [20–23]. VEGFs mediate angiogenic signals to the vas-
cular endothelium via high afﬁnity receptor tyrosine kinases,
designated soluble VEGF receptors-1 [soluble fms-like tyrosine
kinase (sFlt)-1] (sVEGFR-1), soluble VEGF receptor-2 [Flk1/
KDR] (sVEGFR-2), and VEGFR-3 (Flt4) [24].
Expression of VEGF and its receptors is increased in the
skin of SSc patients [25,26]. Soluble Flt-1 (sFlt-1) is an endoge-
nous inhibitor of VEGF given that it is a variant form of
VEGF receptor 1 (VEGFR-1) that lacks the transmembrane
and intracellular domains of VEGFR-1 yet binds to VEGF
with the same afﬁnity as VEGFR-1 and therefore blocks
VEGF function. It is an endogenous anti-VEGF that may
cause microangiopathy [27] and is associated with endothelial
dysfunction in chronic kidney diseases (CKD) [28]. They are
expressed in atherosclerotic and restenotic lesions as well as
in post-injury rat aortic intimal thickening but not in normal
tunica media [10–13]. In another study, the increase in soluble
Flt-1 was associated with a particularly high risk of severe fetal
growth restriction [29]. The recently discovered sVEGFR-2 has
shown potent antiangiogenic effects [30]. We need to know theeh S et al. Serum vascular endothelial gr
ical manifestations and capillaroscopylevels and ratios of these angiogenic and antiangiogenic factors
(VEGF/sVEGFR-1 and VEGF/sVEGFR-2) in different dis-
eases with angiogenic disturbance.
In this study, we determined the serum levels of VEGF as
an angiogenic factor and sVEGFR-1 and 2 (as anti-
angiogenic factors) in SSc patients compared with healthy con-
trols as a risk factor in the pathogenesis of scleroderma. Also,
the correlation of these factors with the main disease manifes-
tations including lung and heart involvement and digital ulcers
as well as to the capillaroscopy ﬁndings has been evaluated.
2. Patients and methods
In this case-control study, 44 Iranian patients who fulﬁlled the
American College of Rheumatology criteria for PSS [31] were
recruited and grouped into patients with limited or diffuse skin
involvement according to a proposed classiﬁcation system [32].
Patients were referred to the scleroderma clinic of Hafez
Hospital of Shiraz University of Medical Sciences, Iran, from
April 2011 to April 2012. Forty four age and sex matched
healthy controls without any rheumatic diseases were also
included. Patients were above 16 years and selected through
random sampling. All patients signed an informed consent
before inclusion in the study. The study was approved by the
Shiraz University of Medical Sciences research ethics commit-
tee and was in accordance to the 1964 Helsinki declaration and
its later amendments. Cases with overlap syndrome, impaired
renal function (GFR< 60 ml/min/1.73 m2), smokers, diabetes
mellitus, active infection and receiving immunosuppressives as
cyclophosphamide, azathioprine, mycophenolate mofetil and
methotrexate were excluded; patients using pred-
nisoloneP 7.5 mg were also excluded from the study.
The demographic and clinical data were collected, pul-
monary involvement assessed by high resolution lung CT scan
(HRCT), skin sclerosis severity assessed by the modiﬁed Rod-
nan skin score (mRss) [33], vascular involvement by digital tip
ulcerations and pulmonary artery hypertension (PAH) deﬁned
by echocardiography; also, if pulmonary artery pressure was
more than 40 mm Hg, it was conﬁrmed by cardiac
catheterization.
Capillaroscopy: It was performed by stereomicroscope
(Euromex ST, 1740, 250 power and video camera Cmex
D.C. 5000, 5 megapixels, Holland). Immersion oil was
applied on nailfold bed to improve the resolution. Eight ﬁn-
gers of the two hands excluding the thumbs were assessed.
The ﬁngers with thick nailfolds and ulcerated ones were not
studied. Data including distribution, shape of capillaries,owth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1) and sVEGFR-2 in
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Table 1 Demographic features, clinical characteristics and
capillaroscopic ﬁndings of the systemic sclerosis patients.
Characteristic mean ± SD (range) or n (%) SSc patients (n= 44)
Age (years) 40.7 ± 12.8 (16–74)
Gender M:F 4:40 (1:9)
Disease duration (months) 56.2 ± 60.6 (2–240)
Subtypes:
-Limited 17 (38.6)
-Diﬀuse 27 (61.4)
mRss score (in 42 patients) 21.48 ± 8.6 (4–41)
Raynaud’s phenomenon 44 (100)
Digital pitting scars 44 (100)
Finger tip ulcers 9 (20)
Interstitial pulmonary ﬁbrosis 4 (9)
Capillaroscopy findings (n= 18)
-Normal 0 (0)
-Nonspeciﬁc change 3 (16.7)
-Early scleroderma pattern 1 (5.5)
-Active scleroderma pattern 11 (61.1)
-Late scleroderma pattern 3 (16.7)
-Dilated loops 18 (100)
-Giant loops 12 (67)
-Neoangiogenesis 10 (55)
-Microhemorrhages 13 (72)
Number of capillaries/mm 3–8
SSc, systemic sclerosis; mRss, modiﬁed Rodnan skin severity.
VEGF, sVEGFR-1 and sVEGFR-2 in systemic sclerosis 3the largest diameter of arterial or venous side (dilated loops:
irregular or homogeneous increase of capillary diameter P20
and <50 lm; giant capillaries: homogeneously enlarged loop
with a diameter P50 lm), capillary length, mean capillary
density, avascular area, microhemorrhages and neoangiogen-
esis or ramiﬁed capillaries (branching, bushy, interconnected
capillaries, originating from a single capillary) were recorded
in a form. The whole ﬁndings were deﬁned as normal, speciﬁc
changes for early, active, and late scleroderma pattern or
non-speciﬁc changes [2]. The available capillaroscopic results
of the patients that were done before and after the time of
blood sampling were reviewed and considered. Even patients
with late SSc pattern by capillaroscopy were not receiving
any previous medications.
Serum levels of VEGF (Quantikine, R&D systems, USA),
sVEGFR-1 (Quantikine, R&D systems, USA) and sVEGFR-
2 (Adipo Bioscience, USA) were measured in all samples using
ELISA kits, according to the manufacturer’s recommenda-
tions. The sensitivity of the kits for VEGF, sVEGFR-1 and
sVEGFR2 was 9.0 pg/ml, 3.5 pg/ml and 15 pg/ml, respectively.
As sVEGFR-1 could play a role in diabetic nephropathy
and CKD, respectively, the estimated creatinine clearance rate
(eCCr) was checked using Cockcroft–Gault formula to ﬁnd the
glomerular ﬁltration rate (GFR) of patients [27,28].
Statistical analysis: Data were analyzed in SPSS, version 16,
using descriptive, Chi-square test, T-test, Man Whitney test,
and Pearson correlation. Results were presented as mean
± SD (range) and as number (percentage). The standard error
was considered to reduce the number digits of the values. The
signiﬁcance level was set as p 6 0.05.
3. Results
The SSc patients had a mean age of 40.7 ± 12.8 years (range:
16–74 years) and had a M:F (1:9). The mean matched age of
the control was 39.4 ± 11.76 years (p> 0.05) and they were
3 males and 41 females. 27 patients (61.4%) had diffuse SSc
and 17 (38.6%) limited. Demographic features, clinical charac-
teristics and capillaroscopic data are shown in Table 1. The
disease duration was 56.2 ± 60.6 months (range: 2–240) being
longer in those with diffuse SSc subtype (72 ± 71.8 months)
compared to those with limited form (56.2 ± 60.6 months)
(p= 0.27). In these patients, none had pulmonary hyperten-
sion or cardiac involvement. Capillaroscopic data were avail-
able for 18 patients.
Mean serum levels of VEGF, sVEGF-R1, sVEGF-R2 as
well as the VEGF/sVEGFR1 and VEGF/sVEGFR2 ratios
were compared between patients and controls (Table 2). Serum
levels of VEGF, sVEGF-R1, and sVEGF-R2 were higher in
patients with diffuse SSc compared to the limited subtype,
but those differences were not signiﬁcant (p= 0.34, p= 0.54
and p= 0.8, respectively). Levels were also comparable
between each one of the disease subtypes and control. Of inter-
est, the levels of VEGF and VEGF/sVEGF-R2 were signiﬁ-
cantly different between diffuse SSc and control (p= 0.014
and p= 0.008, respectively).
Mean serum levels of VEGF (444.4 pg/ml), sVEGF-R1
(1203.5 pg/ml) and sVEGF-R2 (2036.3 pg/ml) and the ratio
of VEGF/sVEGFR1 (2.4) and VEGF/sVEGFR2 (0.22) in
patients with active, early and nonspeciﬁc scleroderma pattern
in their capillaroscopy were higher in comparison to patientsPlease cite this article in press as: Shenavandeh S et al. Serum vascular endothelial gr
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ejr.2016.03.004with late scleroderma pattern (256.5 pg/ml, 71.3 pg/ml,
955.8 pg/ml, 4.9 and 0.43 respectively) and these levels reached
the signiﬁcant level only for sVEGF-R2 (p= 0.6, p= 0.2,
p= 0.04, p= 0.5 and p= 0.4, respectively) (Fig. 1).
There was no signiﬁcant correlation between the serum
levels of VEGF with that of sVEGF-R1 and sVEGF-R2 in
the control (r= 0.09, p= 0.56; r= 0.15, p= 0.32 respec-
tively). There was a signiﬁcant correlation between serum
VEGF and sVEGF-R1 in SSc patients (r= 0.43, p= 0.004).
But no correlation was seen between VEGF and sVEGF-R2
in patients (p= 0.09, r= 0.26). There was no correlation
between all the studied parameters and disease duration or
with the GFR (checked in 23 patients) (p> 0.05).
sVEGF-R1 and sVEGF-R2 serum levels in patients with
digital tip ulceration were lower (p= 0.54 and p= 0.8
respectively) while VEGF levels were higher (p= 0.34) com-
pared to those without although the difference was not signif-
icant (Table 3). Levels of VEGF, sVEGF-R1, sVEGF-R2
and the ratio of VEGF/sVEGFR1 and VEGF/sVEGFR2
were not signiﬁcantly different between patients with and
without interstitial pulmonary ﬁbrosis (p= 0.52, p= 0.7,
p= 0.7, p= 0.12, and p= 0.74, respectively) (Table 4).
There was no association between the presence of dilated
loops, giant loops, neoangiogenesis, microhemorrhages, avas-
cular areas or the number of capillaries in each millimeter of
their nail bed with the VEGF, sVEGF-R1 and sVEGF-R2
(p > 0.05). There was a signiﬁcant correlation between the
mRss and levels of VEGF (r= 0.31, p= 0.04). sVEGF-R1
and sVEGF-R2 did not show a signiﬁcant correlation with
the skin severity score (r= 0.15, p= 0.36, and r= 0.01,
p= 0.96, respectively).owth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1) and sVEGFR-2 in
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Table 2 Serum levels of VEGF, sVEGF-R1, sVEGF-R2 and their ratios in systemic sclerosis patients and control.
Mean ± SE
(range)
VEGF (pg/ml) sVEGF-R1 (pg/ml) sVEGF-R2 (pg/ml) VEGF/VEGF-R1 VEGF/VEGF-R2
SSc patients 363.4 ± 133.9 (0–4647.9) 816.5 ± 356.6 (0–13072.4) 2039.6 ± 109 (518.2–3488.4) 1.7 ± 0.3 (0–7.6) 0.18 ± 0.1 (0–1.75)
Diﬀuse 514.4 ± 1167 (0–4647.9) 1177.7 ± 2970 (0–13072.4) 2066.2 ± 761 (699.2–3488.4) 1.89 ± 2.4 (0–7.6) 0.23 ± 0.4 (0–1.75)
Limited 181.6 ± 310 (0–1181.5) 473.9 ± 1521 (0–5758.2) 1926.2 ± 795 (518.2–2963.9) 1.48 ± 1.7 (0–5.5) 0.12 ± 0.15 (0–0.49)
Control 93.9 ± 25.2 (1–884.66) 1025.6 ± 900.9 (1–39728.8) 2366 ± 116.5 (80.79–4267.14) 34.7 ± 20.4 (0–884.7) 0.08 ± 0.04 (0–1.62)
P-value1 0.05 0.9 0.04 0.61 0.38
P-value2 0.014 0.85 0.1 0.49 0.008
P-value3 0.4 0.42 0.17 0.19 0.36
SSc, systemic sclerosis; VEGF, vascular endothelial growth factor; sVEGF-R1, soluble VEGF receptor-1; sVEGF-R2, soluble VEGF
receptor-2. P-value 1: between SSc patients and control. P-value 2: between diffuse SSc patients and control. P-value 3: between limited SSc
patients and control. Bold values are signiﬁcant at p 6 0.05.
Figure 1 (a) Active scleroderma pattern of nailfold capillaroscopy showing multiple giant loops and microhemorrhages without
neoangiogenesis, (b) late scleroderma pattern of capillaroscopy showing decreased number of capillaries with ramiﬁcation and
neoangiogenesis.
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The results of the present study indicating higher VEGF levels
in the sera of SSc patients compared to healthy controls are in
agreement with previous studies [17,19,25,26]. Accordingly,
overproduction of VEGF as an angiogenic factor in SSc might
play an important role in pathophysiology of the disease.
Unlike VEGF, the levels of sVEGF-R2 (as an anti-
angiogenic factor) in the sera of SSc patients were signiﬁcantly
lower than those in healthy controls. Therefore, failure to pro-
duce sufﬁcient amount of sVEGF-R2 might involve in SSc
pathogenesis. Consequently, administration of sVEGF-R2
might be considered as a new approach for treatment of SSc
patients. In disharmony to another study [34] that reported
lower concentrations of sVEGFR-1 in SSc patients comparedPlease cite this article in press as: Shenavandeh S et al. Serum vascular endothelial gr
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ejr.2016.03.004to controls, we did not ﬁnd any signiﬁcant difference. A possi-
ble reason for this difference could be that they included 659
SSc patients and 511 controls. Moreover, in concordance with
another study [35], the results of the present work showed a
tendency to increase in the VEGF/sVEGF-R2 ratio in patients
compared to controls. It is thus suggested that high levels of
VEGF and lower levels of sVEGF-R2 predispose to SSc. On
the other hand, higher levels of VEGF were reported in diffuse
SSc patients compared to limited ones [19]. In agreement, the
results of the present study also showed a tendency to higher
levels of all the above mentioned factors in diffuse compared
to limited SSc patients.
In the present study, the possible association of VEGF or
its soluble receptors with different clinical manifestations was
also investigated. In the present study, due to the limitedowth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1) and sVEGFR-2 in
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Table 3 Serum levels of VEGF, sVEGF-R1, sVEGF-R2 and their ratios in systemic sclerosis patients with and without digital tip
ulcers.
Mean ± SE (range) Systemic sclerosis patients (n= 44)
VEGF (pg/ml) VEGF-R1 (pg/ml) VEGF-R2 (pg/ml) VEGF/VEGF-R1 VEGF/VEGF-R2
Digital ulcer
With (n= 9) 674.4 ± 500.9
(1–4647.9)
522.9 ± 478.5
(0–4349.8)
1876.02 ± 347.4
(518.2–3488.4)
15.1 ± 12.4
(0.01–113.9)
0.3 ± 0.14
(0–1.3)
Without (n= 35) 312.2 ± 129.01
(1–3812.2)
1011.6 ± 502.6
(1–13072.4)
2085.3 ± 121.5
(699.2–3362.7)
25.4 ± 16.4
(0–453.6)
0.16 ± 0.06
(0–1.75)
p 0.34 0.54 0.8 0.5 0.32
SSc, systemic sclerosis; VEGF, vascular endothelial growth factor; sVEGF-R1, soluble VEGF receptor-1; sVEGF-R2, soluble VEGF
receptor-2.
Table 4 Serum levels of VEGF, sVEGF-R1, sVEGF-R2 and their ratios in systemic sclerosis patients with and without interstitial
pulmonary ﬁbrosis.
Mean ± SE (range) Systemic sclerosis patients (n= 44)
VEGF (pg/ml) VEGF-R1 (pg/ml) VEGF-R2 (pg/ml) VEGF/VEGF-R1 VEGF/VEGF-R2
IPF
With (n= 4) 190.4 ± 63.9
(75.8–370.2)
2227.3 ± 110.4
(1916.2–2423)
79.2 ± 12.4
(55.6–110)
2.7 ± 1.3
(1.19–6.65)
0.08 ± 0.02
(0.03–0.17)
Without (n= 40) 380.6 ± 465
(0–4647.9)
2020.8 ± 377
(518.2–3488.4)
890.1 ± 1235.5
(0–13072.4)
1.4 ± 1
(0–7.58)
0.1 ± 0.1
(0–1.76)
p 0.52 0.68 0.67 0.12 0.74
SSc, systemic sclerosis, IPF, interstitial pulmonary ﬁbrosis; VEGF, vascular endothelial growth factor; sVEGF-R1, soluble VEGF receptor-1;
sVEGF-R2, soluble VEGF receptor-2.
VEGF, sVEGFR-1 and sVEGFR-2 in systemic sclerosis 5number of patients with interstitial pulmonary ﬁbrosis (n= 4),
we could not ﬁnd any signiﬁcant association with the studied
factors. However, in a previous study, a signiﬁcant association
was found between VEGF and interstitial lung disease [36]. Of
interest, a signiﬁcant correlation was only detected between the
levels of VEGF and skin score (mRss). Hence, VEGF might be
involved in the induction of pathologic changes of skin in SSc.
Lower levels of sVEGF-R2 were seen in patients with late
scleroderma pattern of capillaroscopy compared to those with
early, active and nonspeciﬁc patterns. Given the fact that
higher neoangiogenesis and ramiﬁcation and lower number
of capillaries are well-known characteristics of the late pattern
of capillaroscopy [2], lower levels of anti-angiogenic sVEGF-
R2 in these patients are expectable. Although when all compo-
nents of capillaroscopy were separately checked, there was no
signiﬁcant association among neoangiogenesis, microhemor-
rhages, giant loops, avascular area and lower number of capil-
laries with all factors. Similar to the present ﬁndings, in a study
done on 44 scleroderma patients no association was found
between scleroderma patterns of nailfold capillaroscopy and
VEGF-A level [36].
In the current patients, and not in the control, we found a
signiﬁcant association between levels of VEGF and sVEGF-
R1 but not with sVEGF-R2 that may again show the signiﬁ-
cance of low sVEGF-R2 in these patients. Overall, the results
of the present study suggest the important possible role of
VEGF or its soluble receptors (VEGF-R1 and sVEGF-R2)
especially sVEGF-R2 in the pathogenesis and clinical manifes-
tations of SSc. However, replication of this study with higherPlease cite this article in press as: Shenavandeh S et al. Serum vascular endothelial gr
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ejr.2016.03.004number of patients without previous history of medications
is recommended.
In conclusion, SSc patients, VEGF, a very potent angio-
genic molecule, is overexpressed while the levels of sVEGF-
R2, an anti-angiogenic factor decreased. Our results suggest
that these factors might be involved in the induction of vascu-
lopathy and may be neoangiogenesis in patients with SSc.
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